Generic Name: Rimonabant
Acomplia is a newer anti-obesity diet pill which was approved in the European Union for the treatment of obesity. However, psychological side effects in many users, such as suicidal thoughts and depression, have resulted in this medication now being removed from the European markets.
Phentramin-D has become the most popular diet pill for its prescription strength formula that boosts energy, burns fat and curbs hunger.
Phentramin-D is the best replacement for popular prescription diet pills such as Phentermine and Adipex.
How does Acomplia work?
Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism. Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis. CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.
What is Acomplia used for?
Acomplia is a diet pill and is used with diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood. Sanofi-aventis, the manufacturer of Acomplia, argues that Acomplia can also prevent the risk of cardiovascular disease. Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.
Does Acomplia also aid smoking cessation?
Acomplia has been studied by sanofi-aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking. Sanofi-aventis submitted a New Drug Application to the FDA, which in turn issued a non approvable letter for Acomplia for use in smoking cessation.
Is Acomplia approved in the United States? No. Sanofi is still awaiting U.S. marketing go-ahead. U.S. health authorities have asked Sanofi for more information on Acomplia and its potential side effects. Acomplia received European Union marketing approval in June 2006, however this approval has been suspended following a number of cases of psychological side effects from taking this drug.
What are the side-effects of Acomplia?
Side effects in the trial on Acomplia in obesity were vomiting and nausea. The most significant side effects were psychiatric problems, in particular depressionAcomplia,